⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026802 | 1.00 | NOS2 (0.43) | — | |
| SCHEMBL15877835 | 1.00 | NOS2 (0.43) | — | |
| SCHEMBL9305499 | 1.00 | — | — | |
| SCHEMBL26781597 | 1.00 | NOS2 (0.43) | — | |
| SCHEMBL7381082 | 1.00 | NOS2 (0.43) | — | |
| SCHEMBL353811 | 1.00 | — | — | |
| Water SCHEMBL29376299 | 0.98 | NOS2 (0.41) | — | |
| SCHEMBL3257162 | 0.98 | NOS2 (0.41) | — | |
| SCHEMBL239908 | 0.92 | — | — | |
| SCHEMBL92737 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4329877-B1 | SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY | ALKERMES INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20240124485-A1 | SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-04-18 | — | — | US | disclosed |
| EP-4329877-A1 | SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY | Alkermes, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20240043410-A1 | SULPHAMOYL UREA DERIVATIVES CONTAINING ALKYL-OXACYCLOALKYL MOIETY AND USES THEREOF | NodThera Limited (GB) | 2024-02-08 | — | — | US | disclosed |
| WO-2024026424-A1 | QUINAZOLINONE DERIVATIVES AS AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-117440955-A | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | 阿尔克姆斯有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117143082-A | Azabicyclo [3.1.0] hexane derivatives useful as 3C-like protease inhibitors | 广州国家实验室 | 2023-12-01 | — | — | CN | disclosed |
| WO-2022261427-A1 | (4-(6-((2-OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)PHENYL)(IMINO)(METHYL)-LAMBDA6- SULFANONE DERIVATIVES AND SIMILAR COMPOUNDS AS MUSCARINIC ACETYLCHOLINE RECEPTOR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | VANDERBILT UNIVERSITY (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022232025-A1 | SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY | ALKERMES, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022212819-A1 | INDAZOLE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022125849-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2022-06-16 | — | — | WO | disclosed |
| CN-114502158-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022051582-A1 | SULPHAMOYL UREA DERIVATIVES CONTAINING ALKYL-OXACYCLOALKYL MOIETY AND USES THEREOF | NodThera Limited (GB) | 2022-03-10 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |